Azacitidine treatment for myeloid leukemia associated with Down syndrome: A nationwide retrospective study in Japan.
Pediatr Blood Cancer
; 71(10): e31244, 2024 Oct.
Article
em En
| MEDLINE
| ID: mdl-39099137
ABSTRACT
Hypomethylating agent treatment for myeloid leukemia associated with Down syndrome (ML-DS) has been scarcely reported. Herein, we collected information on azacitidine treatment for ML-DS in Japan. Forty-eight cycles of azacitidine treatment were performed for 12 patients, including 11 relapsed or refractory (R/R) patients. In 40 cycles, azacitidine was used as monotherapy. No azacitidine-related death was observed. One cycle concurrently administered with methotrexate-based intrathecal therapy was discontinued due to toxicities. Only 4 of the 19 cycles given in non-remission achieved complete or partial remission. In conclusion, although most toxicities were acceptable, azacitidine monotherapy might be insufficient for R/R ML-DS cases.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Azacitidina
/
Leucemia Mieloide
/
Síndrome de Down
/
Antimetabólitos Antineoplásicos
Limite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
País/Região como assunto:
Asia
Idioma:
En
Revista:
Pediatr Blood Cancer
Ano de publicação:
2024
Tipo de documento:
Article